[{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"||Dopamine D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"||D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"||D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam","moa":"||D1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"University of California, Riverside | Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ecopipam","moa":"||Dopamine D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ University of California, Riverside | Premier Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ University of California, Riverside | Premier Research Group"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ecopipam","moa":"||D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ University of California"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ecopipam","moa":"||D1 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ University of California"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Covance","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ecopipam","moa":"||Dopamine D1 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Emalex Bioscience \/ Covance","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ Covance"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Syneos Health | Nuventra","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Ecopipam HCl","moa":"||DRD1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Syneos Health | Nuventra","highestDevelopmentStatusID":"6","companyTruncated":"Emalex Bioscience \/ Syneos Health | Nuventra"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Syneos Health | Nuventra","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Divalproex Sodium","moa":"||DRD1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Emalex Bioscience \/ Syneos Health | Nuventra","highestDevelopmentStatusID":"6","companyTruncated":"Emalex Bioscience \/ Syneos Health | Nuventra"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Ecopipam HCl","moa":"||DRD1","graph1":"Neurology","graph2":"Phase III","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Icon Plc | Nuventra","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ecopipam","moa":"||Dopamine D1 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emalex Bioscience \/ Icon Plc | Nuventra","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ Icon Plc | Nuventra"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Syneos Health | Cambridge Cognition","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Itraconazole","moa":"||Cytochrome P450 51","graph1":"Undisclosed","graph2":"Phase I","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emalex Bioscience \/ Syneos Health | Cambridge Cognition","highestDevelopmentStatusID":"6","companyTruncated":"Emalex Bioscience \/ Syneos Health | Cambridge Cognition"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ecopipam","moa":"||Dopamine D1 receptor","graph1":"Undisclosed","graph2":"Phase II","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Emalex Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Emalex Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Emalex Bioscience","sponsor":"PPD | Bioclinica","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Ecopipam HCl","moa":"||DRD1","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Emalex Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emalex Bioscience \/ PPD | Bioclinica","highestDevelopmentStatusID":"6","companyTruncated":"Emalex Bioscience \/ PPD | Bioclinica"}]
Find Clinical Drug Pipeline Developments & Deals by Emalex Bioscience
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
